The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.d

Pleural/pericardial effusion, ANA positive (DI lupus)

Publications

Gupta R, Hennebry TA, Kinasewitz GT

Pleuropericardial effusion after 37 years of sulfasalazine therapy.

Journal of cardiovascular medicine (Hagerstown, Md.). 2012;13(8):541-3

Camus P, Piard F, Ashcroft T, Gal AA, Colby TV

The lung in inflammatory bowel disease.

Medicine. 1993;72(3):151-83

Vanheule BA, Carswell F

Sulphasalazine-induced systemic lupus erythematosus in a child.

European journal of pediatrics. 1983;140(1):66-8

Clementz GL, Dolin BJ

Sulfasalazine-induced lupus erythematosus.

The American journal of medicine. 1988;84(3 Pt 1):535-8

Deboever G, Devogelaere R, Holvoet G

Sulphasalazine-induced lupus-like syndrome with cardiac tamponade in a patient with ulcerative colitis.

The American journal of gastroenterology. 1989;84(1):85-6